Subscribe To
KNTE / Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
KNTE News
By Zacks Investment Research
October 3, 2023
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization more_horizontal
By GlobeNewsWire
March 14, 2023
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision onco more_horizontal